Bilateral uveitis and macular edema induced by Nivolumab: a case report

doi:10.1186/s12886-017-0611-3

Case Reports

. 2017 Dec 1;17(1):227.

doi: 10.1186/s12886-017-0611-3.

Bilateral uveitis and macular edema induced by Nivolumab: a case report

Claire Theillac^{1

2}, Morgane Straub^{3

4}, Anne-Laure Breton^{5

3}, Luc Thomas^{5

3

6}, Stéphane Dalle^{5

3

6}

Affiliations

¹ Department of Dermatology, Service de dermatologie, ImmuCare, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 chemin du grand revoyet, Pierre Bénite Cedex, France. claire.theillac@chu-lyon.fr.
² Université Claude Bernard Lyon 1, Lyon, France. claire.theillac@chu-lyon.fr.
³ Université Claude Bernard Lyon 1, Lyon, France.
⁴ Department of Ophthalmology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.
⁵ Department of Dermatology, Service de dermatologie, ImmuCare, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 chemin du grand revoyet, Pierre Bénite Cedex, France.
⁶ Cancer Research Center of Lyon, Lyon, France.

PMID: 29195497
PMCID: PMC5709862
DOI: 10.1186/s12886-017-0611-3

Case Reports

Bilateral uveitis and macular edema induced by Nivolumab: a case report

Claire Theillac et al. BMC Ophthalmol. 2017.

. 2017 Dec 1;17(1):227.

doi: 10.1186/s12886-017-0611-3.

Authors

Claire Theillac^{1

2}, Morgane Straub^{3

4}, Anne-Laure Breton^{5

3}, Luc Thomas^{5

3

6}, Stéphane Dalle^{5

3

6}

Affiliations

¹ Department of Dermatology, Service de dermatologie, ImmuCare, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 chemin du grand revoyet, Pierre Bénite Cedex, France. claire.theillac@chu-lyon.fr.
² Université Claude Bernard Lyon 1, Lyon, France. claire.theillac@chu-lyon.fr.
³ Université Claude Bernard Lyon 1, Lyon, France.
⁴ Department of Ophthalmology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.
⁵ Department of Dermatology, Service de dermatologie, ImmuCare, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 chemin du grand revoyet, Pierre Bénite Cedex, France.
⁶ Cancer Research Center of Lyon, Lyon, France.

PMID: 29195497
PMCID: PMC5709862
DOI: 10.1186/s12886-017-0611-3

Abstract

Background: Nivolumab is a fully human antibody which is routinely used at first therapy for metastatic melanoma. Usually, side effects are immune-related adverse events. We report a case of a man who developed bilateral anterior uveitis and macular serous retinal detachment during nivolumab treatment for metastatic melanoma.

Case presentation: A man on nivolumab treatment for a leg melanoma with duodenal and lymph nodes metastases developed a sudden bilateral visual acuity impairment and bilateral non-painfull redness eyes several days after the third infusion. The clinical examination showed a significant decreased of the visual acuity. Slit lamp examination revealed the presence of bilateral granulomatous keratic precipitates, anterior chamber cells +++, bilateral synechiae, bilateral papilledema and macular edema associated with serous retinal detachment in the left eye. The anti-Programmed cells Death-1 was stopped and a topical corticosteroid treatment was administrated. After 8 days of topical corticosteroid treatment visual acuity was worsening with similar optical coherence tomography examination. An oral corticosteroid treatment was started. Evolution was favorable with a decrease of ocular inflammation and a complete visual acuity recovery after 3 weeks. Nivolumab was re-initiated.

Conclusions: This is the second clinical report of bilateral anterior uveitis associated with macular serous retinal detachment related to anti-PD-1 treatment, and the first with nivolumab. Cases of uveitis were reported several times. Although rare, ophthalmologic manifestations that are rapidly recognized and adequately managed can be treated.

Keywords: Immunotherapy; Macular edema; Melanoma; Side-effect; Uveitis.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

**Fig. 1**
Bilateral slit lamp examination: OD and OS: posterior synechiae (red arrows)

**Fig. 2**
Right eye fluorescein angiography with papillitis (early stage 2:39 min)

**Fig. 3**
Bilateral optical coherence tomography: OD: normal foveolar profile before and after treatment, OS: retrofoveal subretinal detachment before and after treatment

See this image and copyright information in PMC

Cited by

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.
Martens A, Schauwvlieghe PP, Madoe A, Casteels I, Aspeslagh S. Martens A, et al. J Ophthalmic Inflamm Infect. 2023 Feb 22;13(1):5. doi: 10.1186/s12348-022-00321-2. J Ophthalmic Inflamm Infect. 2023. PMID: 36811715 Free PMC article. Review.
Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis.
Tian Y, Huang A, Tian M, Wang K, Dang Q, Zhang C, Liu H, Zhao J, Yang X, Zhang C, Guo L, Chen F. Tian Y, et al. Medicine (Baltimore). 2022 Sep 9;101(36):e30151. doi: 10.1097/MD.0000000000030151. Medicine (Baltimore). 2022. PMID: 36086680 Free PMC article.
_targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.
Bindiganavile SH, Bhat N, Lee AG, Gombos DS, Al-Zubidi N. Bindiganavile SH, et al. J Immunother Precis Oncol. 2021 Feb 25;4(1):6-15. doi: 10.36401/JIPO-20-21. eCollection 2021 Feb. J Immunother Precis Oncol. 2021. PMID: 35664825 Free PMC article. Review.
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.
Albarrán-Artahona V, Laguna JC, Gorría T, Torres-Jiménez J, Pascal M, Mezquita L. Albarrán-Artahona V, et al. Diagnostics (Basel). 2022 Aug 29;12(9):2091. doi: 10.3390/diagnostics12092091. Diagnostics (Basel). 2022. PMID: 36140493 Free PMC article. Review.
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma.
Obata S, Saishin Y, Teramura K, Ohji M. Obata S, et al. Case Rep Ophthalmol. 2019 Feb 8;10(1):67-74. doi: 10.1159/000496682. eCollection 2019 Jan-Apr. Case Rep Ophthalmol. 2019. PMID: 31097947 Free PMC article.

See all "Cited by" articles

References

1. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi: 10.1056/NEJMoa1412082. - DOI - PubMed
1. Schmid-Bindert G, Jiang T. First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and ‘the sorcerers apprentice. Transl Lung Cancer Res. 2015;4(3):215–216. - PMC - PubMed
1. Larkin J, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1(4):433–440. doi: 10.1001/jamaoncol.2015.1184. - DOI - PubMed
1. Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs Clin Immunother Biopharm Gene Ther. 2016;30(6):571–584. - PubMed
1. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. doi: 10.1172/JCI80011. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi: 10.1056/NEJMoa1412082. - DOI - PubMed

[2] Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi: 10.1056/NEJMoa1412082. - DOI - PubMed

[3] Schmid-Bindert G, Jiang T. First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and ‘the sorcerers apprentice. Transl Lung Cancer Res. 2015;4(3):215–216. - PMC - PubMed

[4] Schmid-Bindert G, Jiang T. First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and ‘the sorcerers apprentice. Transl Lung Cancer Res. 2015;4(3):215–216. - PMC - PubMed

[5] Larkin J, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1(4):433–440. doi: 10.1001/jamaoncol.2015.1184. - DOI - PubMed

[6] Larkin J, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1(4):433–440. doi: 10.1001/jamaoncol.2015.1184. - DOI - PubMed

[7] Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs Clin Immunother Biopharm Gene Ther. 2016;30(6):571–584. - PubMed

[8] Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs Clin Immunother Biopharm Gene Ther. 2016;30(6):571–584. - PubMed

[9] Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. doi: 10.1172/JCI80011. - DOI - PMC - PubMed

[10] Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. doi: 10.1172/JCI80011. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed